Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Khiron Life Sciences's Revenue for the
three
months ended in Sep. 2022 was $2.54 Mil. Khiron Life Sciences's average Accounts Receivable for the
three
months ended in Sep. 2022 was $3.30 Mil.
Hence, Khiron Life Sciences's Receivables Turnover for the
three
months ended in Sep. 2022 was 0.77.
Khiron Life Sciences (OTCPK:KHRNF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Khiron Life Sciences Receivables Turnover Related Terms
Khiron Life Sciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Khiron Life Sciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KHRNF vs ZTS, CTLT, VTRS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Khiron Life Sciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Khiron Life Sciences Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Khiron Life Sciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Khiron Life Sciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Khiron Life Sciences (KHRNF) has a Receivables Turnover of 0.77 as of Sep. 2022. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Khiron Life Sciences and its competitors.
Is Khiron Life Sciences' Receivables Turnover too high?
Khiron Life Sciences' current Receivables Turnover is 0.77. The Drug Manufacturers industry median Receivables Turnover is 5.06. Khiron Life Sciences' value of 0.77 is 84.8% below this industry median.
How does Khiron Life Sciences' Receivables Turnover compare to ZTS and CTLT?
Khiron Life Sciences' Receivables Turnover of 0.77 can be compared against companies in the Drug Manufacturers industry. The industry median Receivables Turnover is 5.06. Khiron Life Sciences' value of 0.77 is 84.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.06, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Khiron Life Sciences's current Receivables Turnover of 0.77 is 84.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Khiron Life Sciences and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Khiron Life Sciences's current Receivables Turnover is 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Khiron Life Sciences stock overvalued right now?
Khiron Life Sciences (KHRNF) has a current Receivables Turnover of 0.77. The current Receivables Turnover is 0.77 and 84.8% below the Drug Manufacturers industry median of 5.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Khiron Life Sciences (KHRNF), the current Receivables Turnover is 0.77 as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Khiron Life Sciences Corp is a vertically integrated medical company with core operations in Latin America and Europe, The company's platform leverages medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The company has a presence in Mexico, Peru, Germany, the United Kingdom, and Brazil.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KHRNF has been successfully added to your 
